Form 4: Humacyte CEO Laura Niklason Sells Shares in Private and Open Market Transactions

Humacyte's CEO, Laura Niklason, indirectly sold shares through Ayabudge LLC and directly held shares in private transactions, while maintaining significant beneficial ownership.

Summary

• Laura Niklason, the President, CEO, and Director of Humacyte, Inc., reported changes in beneficial ownership of the company's common stock.
• On June 11, 2024, 282,000 shares were sold in a private transaction at $7.0922 per share to a trust controlled by family members.
• On June 11 and 12, 2024, Ayabudge LLC, an entity controlled by Brady W. Dougan, sold 76,630 and 271,518 shares at weighted average prices of $7.02 and $7.3, respectively.
• These sales by Ayabudge LLC were to pay down leverage and provide a mechanism for investors to acquire shares.
• Dr. Niklason is treated as indirectly beneficially owning the shares sold by Ayabudge LLC.
• Following these transactions, Dr. Niklason indirectly beneficially owns 4,559,140 shares through Ayabudge LLC, 1,148,240 shares through The Niklason Living Trust, and 510,161 shares through her spouse, and directly owns 240,832 shares.
• The reporting person has undertaken to provide full information regarding the number of shares sold at each separate price within the ranges provided upon request to the SEC staff or any stockholder of the Issuer.

Sentiment

Score: 5

Explanation: The sentiment is neutral. While there are sales of shares by the CEO, the explanation provided regarding the private transaction and Ayabudge LLC's activities suggests these are not necessarily indicative of negative sentiment towards the company's prospects.

Positives

• The sales by Ayabudge LLC provided a mechanism for investors to acquire shares of Humacyte at a time when the issuer was not conducting a financing transaction.

Industry Context

Insider trading activity is closely monitored in the biotech industry, especially for companies like Humacyte that are in a growth phase and subject to regulatory milestones. Sales by insiders can sometimes be interpreted negatively by the market, but in this case, the explanation provided regarding Ayabudge LLC's transactions and the private sale to family members may mitigate concerns.

Comparison to Industry Standards

• Comparing Humacyte's insider trading activity to companies like CRISPR Therapeutics or BioNTech, which also have high insider ownership, can provide context.
• For example, if executives at CRISPR Therapeutics or BioNTech were to sell shares, the market reaction would depend on the size of the sale, the stated reason, and the overall company performance.
• Similar to Humacyte, these companies' insider transactions are scrutinized for any potential impact on investor confidence.

Related Party Transactions

• The sale of 282,000 shares to a trust controlled by family members of the Reporting Person is a related party transaction.

Stakeholder Impact

• The share sales could potentially impact shareholder confidence, depending on how the market interprets the transactions.
• The explanation provided regarding the reasons for the sales may help to mitigate any negative impact.

Key Dates